ArticleHuman vaccines & immunotherapeutics2021
Universal palivizumab prophylaxis for children with Down syndrome in Japan: analysis with interrupted time-series.
Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 8 citations in OpenAlex.
- Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease.Drug, healthcare and patient safety · 2023Review
- Clinical epidemiology and pharmacoepidemiology studies with real-world databases.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2022Review
- Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome.Frontiers in immunologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Down syndrome (DS) is an independent risk factor for severe respiratory syncytial virus (RSV) infection. Palivizumab - passive immunization for RSV - is the only pharmacological measure for preventing severe disease. In most countries, palivizumab is indicated in young children with congenital heart disease, premature birth, and chronic lung disease. In Japan, since 2013, children with DS, but without such "standard" risk factors, have been able to receive insurance-covered palivizumab prophylaxis, but its effectiveness of policy is unknown. From a nationwide database, we extracted data of children with DS who hospitalized for RSV-related lower respiratory infections (LRTIs), from April 2010 to January 2019. Using an interrupted time-series design, we analyzed data from before and after the introduction of the universal palivizumab prophylaxis program for DS children in Japan. As a result, we identified a total of 152 RSV-related LRTIs in 147 children hospitalized with DS. With time-series analysis, we did not observe a significant change in both level (-1.07,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.